Tobramycin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Tobramycin: From Bacterial Infections to Exposure Keratitis
One-Sentence Summary
Tobramycin is an aminoglycoside antibiotic originally used to treat serious bacterial infections, particularly those caused by Pseudomonas aeruginosa (e.g., ophthalmic infections, pulmonary infections in cystic fibrosis). The TxGNN model predicts it may be effective for Exposure Keratitis, but this is currently supported only by 2 indirect clinical trials and 7 preclinical/case-report publications — no study has evaluated Tobramycin directly in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (aminoglycoside antibiotic, particularly active against Pseudomonas aeruginosa) |
| Predicted New Indication | Exposure Keratitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Tobramycin is an aminoglycoside antibiotic that binds the bacterial 30S ribosomal subunit, inhibiting protein synthesis and producing bactericidal activity — with particular potency against Gram-negative organisms such as Pseudomonas aeruginosa. This underlies its established use as a topical ophthalmic antibiotic and as an inhaled therapy for chronic pulmonary infection in cystic fibrosis.
Exposure keratitis results from inadequate eyelid closure, leaving the corneal surface desiccated and vulnerable to secondary bacterial infection, frequently involving Pseudomonas and other Gram-negative pathogens. Tobramycin’s existing ophthalmic formulation and antipseudomonal spectrum make it mechanistically plausible as an adjunct to prevent or treat secondary bacterial keratitis in exposure keratitis patients — though it would not address the underlying eyelid closure defect itself.
However, none of the identified clinical trials or literature directly studied Tobramycin in exposure keratitis. The trials involve unrelated interventions (viral dendritic ulcer treatment comparison, PRF membrane therapy), and the literature is dominated by case reports of unrelated pathogens and in-vitro corneal toxicity studies. The mechanistic rationale is therefore extrapolated rather than directly demonstrated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05313828 | N/A | Unknown | 40 | Compared treatment modalities for HSV dendritic viral corneal ulcers; not a Tobramycin-specific trial |
| NCT06200727 | N/A | Unknown | 170 | Evaluated platelet-rich fibrin (PRF) membrane in ophthalmic conditions including corneal ulcer; no direct Tobramycin arm |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2707046 | 1989 | In vitro toxicity study | Current Eye Research | Assessed corneal epithelial cytotoxicity of aminoglycosides (incl. tobramycin) in a rabbit model |
| 17228760 | 2006 | In vitro MIC/PAE study | Nippon Ganka Gakkai Zasshi | Compared MIC and postantibiotic effect of antibiotic eye drops against infectious keratitis isolates |
| 34987857 | 2021 | Case report | Oxford Medical Case Reports | Bacterial keratitis caused by multidrug-resistant Shewanella algae without marine exposure |
| 11581057 | 2001 | Case report | Ophthalmology | Bacillus cereus keratitis associated with contact lens wear |
| 12861116 | 2003 | Case report | Eye & Contact Lens | Bilateral MRSA keratitis following photorefractive keratectomy |
| 14574976 | 2003 | Case report | Yan Ke Xue Bao | Paracentral corneal dellen in Graves ophthalmopathy (non-infectious) |
| 33847093 | 2021 | Veterinary case series | Polish Journal of Veterinary Sciences | Feline ocular toxoplasmosis seroprevalence and treatment outcomes (non-human) |
Safety Considerations
Drug Interactions: 131 total interactions identified. Notable Major-severity interactions:
- Magnesium sulfate — increased risk of neuromuscular blockade/respiratory depression when co-administered with aminoglycosides
- Mannitol — increased risk of nephrotoxicity/ototoxicity
Additional Moderate-severity interactions involve other nephro-/ototoxic or absorption-affecting agents, including Vancomycin, Amphotericin B (conventional and lipid complex), Neomycin, Kanamycin, several proton pump inhibitors (Omeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, Rabeprazole), and aminosalicylates (Mesalazine, Balsalazide, Sulfasalazine, Olsalazine).
No package insert–derived key warnings or contraindications are currently available; please refer to the official package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or literature evidence directly evaluates Tobramycin in exposure keratitis — all identified evidence is indirect (unrelated interventions, case reports of unrelated pathogens, in-vitro toxicity data). This is compounded by a Blocking-severity data gap in regulatory safety labeling (TFDA warnings/contraindications), which prevents initial S1 safety screening, and the drug currently has zero registrations/Not Marketed status in India.
To proceed, the following is needed:
- Obtain official package insert / regulatory safety labeling (resolves Blocking gap DG001)
- Confirm detailed mechanism of action documentation (resolves High-priority gap DG002)
- Identify or design a study evaluating topical/ophthalmic Tobramycin specifically for secondary bacterial infection prevention in exposure keratitis
- Assess India market entry feasibility given current “Not Marketed” status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.